Delivery Order SPE2DB24D2106-SPE2DB24FAUST
Award Date
8/19/24
Potential Completion Date
8/20/24
Potential Value
$5.4K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This federal contract award issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The contract is a firm fixed-price delivery order with a ceiling value of $1,631.03 and a completion date of October 29, 2024. DMS Pharmaceutical Group Inc. is the prime contractor and this order is issued under a larger $499,999,999 Indefinite Delivery Contract (IDC) the company...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract is for the delivery of a pharmaceutical product, Quillivant XR 25 mg/5 ml suspension, with a ceiling value of $2,076.13. The contract has a firm fixed-price pricing type and is a delivery order with an ultimate completion date of April 5, 2024. This award appears to be part of a larger indefinite delivery contract (IDV) that DMS...
This federal contract award, valued at $3,817.57, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension, a pharmaceutical product. The award is made under a larger indefinite delivery vehicle (IDV) contract, SPE2DB24D2106, that DMS Pharmaceutical Group holds with DLA. This single-award IDV, valued up to $4,999,999 through 2025, enables DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,366.07 contract is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a performance period ending on May 20, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the agency to issue delivery orders for a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,451.98 firm fixed-price delivery order is for the supply of 120 ml bottles of the prescription medication Quillivant XR (25 mg/5 ml suspension). The award is not associated with a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a ceiling value of $2,280.55. The contract has a period of performance through July 16, 2024. The contract is issued under the DLA's SPE2DB pharmaceutical prime vendor program, a single-award indefinite delivery contract (IDC) valued...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The contract has a ceiling value of $2,371.46 and a final completion date of July 31, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $1,314.20, is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a period of performance through May 13, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the agency to issue...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...